Nasal Drug Delivery With A Focus On Chronic Rhino-Sinusitis

Aptar Pharma recently hosted a scientific roundtable on “Nasal drug delivery with a focus on chronic rhino‑sinusitis”. This international scientific forum was held in Paris, France on November 13th 2012. The roundtable was organized to explore and exchange views on the science of various forms of sinusitis and its related unmet medical needs. It is estimated that around 20% of the population indeveloped countries suffers at any one time with rhino‑sinusitis type symptoms, and the prevalence of CRS (chronic rhino-sinusitis) has been on the increase over the last 30 years 1,2.

Spotlight

Merck Group

Not intended for US & CA visitors. At the biopharma business of Merck, we have an enduring commitment and focus in our specialist therapeutic areas of oncology, neurodegenerative diseases, fertility and endocrinology, along with rheumatology as an emerging area of expertise. We also provide a portfolio of cardiometabolic care and general medicine products, especially in emerging markets where patient need remains high.

OTHER WHITEPAPERS
news image

Ultrasafe film Ultra-high barrier Product stability Patient safety

whitePaper | December 22, 2022

Every viable pharmaceutical packaging system must comprise materials proven to protect its contents against moisture and other atmospheric variables, and be safe for use with the specified dosage form and the route of administration1

Read More
news image

Pharma R&D Annual Review

whitePaper | March 15, 2022

Successes in 2021 – New active substance drug launches

Read More
news image

The convergence of the pharmaceutical and medicaldevices industries

whitePaper | May 26, 2022

The medical device and pharmaceutical industries each share in a mission to improve health outcomes, from prevention to intervention. As a result of this shared mission, integration and overlap between these two industries has been taking place for decades.

Read More
news image

Association for Accessible Medicines Drug Shortages

whitePaper | June 22, 2023

Generic medicines are the backbone of the U.S. prescription drug market, supplying more than 9 out of every 10 prescriptions. And the availability of generic medicines overall is remarkably stable even during challenges such as the COVID-19 pandemic.

Read More
news image

Best practices in viral vector analytical characterization

whitePaper | December 13, 2022

Viral vectors are a critical part of the advanced therapies supply chain as they are used to introduce the gene of interest, whether that’s into a cell intended for therapeutic gene transfer or for direct viral-mediated gene transfer into the patient.

Read More
news image

Manual No More: Automating the Scientific Data Lifecycle

whitePaper | May 23, 2022

The world’s scientific data today is a morass. 50-80% of research scientist and data scientist time is spent wrestling with data before they can focus on highervalue AI/ML and advanced analysis to help bring new life-saving therapeutics to market.

Read More

Spotlight

Merck Group

Not intended for US & CA visitors. At the biopharma business of Merck, we have an enduring commitment and focus in our specialist therapeutic areas of oncology, neurodegenerative diseases, fertility and endocrinology, along with rheumatology as an emerging area of expertise. We also provide a portfolio of cardiometabolic care and general medicine products, especially in emerging markets where patient need remains high.

Events